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Materials and Methods: A MC treatment verification solution 
was implemented on CloudMC, a cloud-based platform 
presented in a previous work. CloudMC runs on Windows 
Azure cloud platform and it had been developed following 
three basic principles: multi-application, elasticity and 
accessibility. It was first designed to parallelize simple MC 
simulations in as many virtual machines as the user selected. 
New features were now added to convert RT plan information 
into text MC input files and to merge the simulation output 
files into a DICOM format dose file that can be compared to 
the one obtained from the planning system. It was also 
necessary to develop a method to distribute the different 
treatment beams calculations among the different virtual 
machines. The MC programs used to perform the 
implementation study were BEAMnrc and DOSxyz, both based 
on the EGSnrc code. CloudMC is independent of the MC code 
used, i.e. the user may use any program based on any other 
MC code provided they fulfill some basic requirements. 
Several tests were carried out to study the times involved in 
the different parts of the process (virtual machines start-up, 
file transfer between machines and the storage system, map-
reduce methods, etc.) and the usage costs of the cloud 
computing resources. 
Results: A complete prostate treatment (25 segments 
distributed in 7 incidences) was simulated using 1.2E9 
primary histories from a 20GB IAEA phase space file. The 
calculation grid was 2x2x5 mm3. The final dose distribution 
had an statistical uncertainty below 1.5% (k=1) in the PTV 
volume. The parallelization was done in 190 small-size virtual 
machines (1 core, 2.2 Ghz, 1.75 GB RAM). The total 
calculation time was 1h and 30 minutes, from which 1h and 
10 min were spent in the MC simulation. The 190 virtual 
machines cluster is created and eliminated in each 
simulation. It needs a start up time that depends on the 
number and size of the machines. In this case, the start up 
time took 7 minutes. The management of the result files 
(2.7GB) was carried out in a medium-size machine. The time 
spent in downloading, merging and uploading the final result 
files was 3 min. The usage cost of this simulation was 15 €. 
Conclusions: The cloud-based application CloudMC has been 
updated with a new feature that allows performing MC 
verifications of RT treatments in a fast, cheap and easy way, 
accessible to any user. The computing power, accessibility 
and low costs make commercial clouds a suitable solution to 
bring MC algorithms closer to daily RT treatment 
calculations. 
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Purpose/Objective: The increasing number of survival 
radiotherapy patients has generated an emergent concern on 
second cancers risks, associated to peripheral doses. Out-of 
field dosimetry of photon and neutron components is still 
under development. Our group established a methodology for 
neutron equivalent dose estimation in organs [1]. In addition, 
an algorithm [2] has been implemented in Philips’ Pinnacle 
TPS for neutron peripheral dose estimation of patients, 
treated with high energy as a part or the totality of their 
treatment. The aim of this study was to present, as an 
example, neutron peripheral doses in pelvic radiotherapy 
treatments to show the high potential of this tool when 
choosing the optimal treatment. 
Materials and Methods: A self-developed Pinnacle script has 
been used for neutron peripheral dose estimation in thirteen 
relevant organs. This study was performed in two centres 
including 2 different machines (3 Siemens Primus and 1 
Siemens Oncor). All of them were previously characterized by 
following the methodology established in [3].  
Pelvic cases that contain high energy (15 or 18 MV) have been 
considered. As neutron doses strongly depend on MU, once 
the facility is characterized, dose estimations are done by 
considering the total number of MU (high energy) and 
choosing patient gender (male/female) and treatment 
location (abdomen/H&N). Population taken into account for 
this study is detailed in the table. Obtained results have been 
compared to previous values [2] where an important cohort 
of patients and machines from 50 facilities were evaluated. 
Table. (see text) 
 
 
Results: The figure shows mean equivalent doses at different 
out-of field organs (mSv) in pelvic (see table) and only 
rectum cases, due to peripheral neutrons from high energy 
radiotherapy treatments. Some representative organs, 
located far from the treatment region, have been considered 
to illustrate neutron peripheral doses. 
When comparing all the pelvic values to previous clinical 
studies [2], considering only the linacs and pathologies 
presented in this work, the mean deviation obtained for 
organ doses is 18%, in the range of uncertainties.  
Figure.  
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Conclusions: This new tool would enable the risk-benefit 
judgements in addition to the rest of the TPS conventional 
parameters, for the optimal treatment choice. The big error 
bars shown in the pelvic cases, are due to the fact of 
considering the mean values of neutron doses obtained for a 
huge variety of treatments and techniques. They decrease 
when considering a more homogeneous inter-centres 
pathology, as the rectum. Treatments that combine low and 
high energies use a lower number of high energy MU and thus 
neutron doses are smaller. This fact should be considered in 
the script for future studies. A good concordance has been 
observed with previous studies [2] for these cases. Future 
works should be carried out to analyse other pathologies for a 
higher number of patients.  
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Purpose/Objective: Multicenter studies for pre-treatment 
planning verifications, sharing methodologies and acceptance 
criteria, could help in developing common procedures 
especially for SBRT treatments. The Italian Association of 
Medical Physics (AIFM) has created a working group dedicated 
to SBRT and one of the first group project was to perform 
pre-treatment quality assurance (QA) of common SBRT plans 
for prostate, liver and lung cancer among different Italian 
centers. 
Materials and Methods: Seventeen centres of the SBRT 
Italian working group verified, in pre-treatment mode, the 
SBRT plans according with their home technologies, 
methodologies and acceptance criteria. A questionnaire 
including personal Gamma criteria, if dose at isocenter was 
verified with ion chamber, Gamma Index results and if QA 
plans were considered deliverable or not. Data are presented 
as averages over the two patients for each anatomical 
district. 
Results: Sixty plans were analysed. The most common 
devices available on commerce were used (Gafchromic films, 
planar and cylindrical array of ion chamber or diode, EPID); 
the Gamma Analysis approach was local for 12 centres and 
global for 5 centres; in 75% of cases, DD and DTA criteria 
were 3%/3mm. For plans related to prostate region, the 
medium Gamma resulted 97.1% (range 92.1-99.7%); four 
centres verified dose at isocenter with a maximum deviation 
of 5.9%; all plans were considered clinically deliverable. For 
Liver region: 93.7% (range 84.9-98.0%); one centre verified 
dose at isocenter with a maximum deviation of 2.7%; two 
plans were considered not acceptable. For Lung region: 95.7% 
(range 86.1-99.0%); two centres verified dose at isocenter 
with a maximum deviation of 9.6%, one plan was considered 
not acceptable. 
 
 
 
 
Conclusions: This project showed differences in terms of the 
parameters considered with possible clinical implication. 
 
 
